Qianben Wang, PhD, has received support for his research on an innovative treatment that has the potential to bring transformative changes in the treatment and management of a lethal form of prostate cancer.
His five-year, $2.63 million National Cancer Institute (NCI) R01 grant will be effective on July 1, 2023, and will fund his work to target the transcriptional coactivator MED31-driven transcription recycling in a lethal type of prostate cancer - castration-resistant prostate cancer (CRPC). His pioneering research project will shed substantial light on the crucial role that transcription recycling plays in CRPC.
Furthermore, it will establish an empirical foundation for upcoming clinical trials. These trials will examine the efficacy and safety of a lipid nanoparticle-delivered CRISPR/Cas13d RNA targeting system, specifically designed to address this novel oncogenic mechanism in CRPC patients.
Pathology Department Chair Jiaoti Huang, MD, PhD, joined forces with Yizhou Dong, PhD, from the Icahn School of Medicine and Victor Jin, PhD, from the Medical College of Wisconsin, as co-investigators on this grant.